Tetraphase Pharmaceuticals Inc Sets New 1-Year High at $16.81 (TTPH)
Tetraphase Pharmaceuticals (NASDAQ:TTPH) set a new 52-week high on Monday, Analyst Ratings.Net reports. The company traded as high as $16.81 and last traded at $15.59, with a volume of 103,993 shares. The stock had previously closed at $15.89.
Several analysts have recently commented on the stock. Analysts at Barclays raised their price target on shares of Tetraphase Pharmaceuticals from $16.00 to $17.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Analysts at Guggenheim initiated coverage on shares of Tetraphase Pharmaceuticals in a research note to investors on Wednesday, November 13th. They set a “buy” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $17.33.
Tetraphase Pharmaceuticals has a one year low of $7.00 and a one year high of $16.50. The stock has a 50-day moving average of $12.71 and a 200-day moving average of $10.46. The company’s market cap is $391.7 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Monday, November 11th. The company reported ($0.49) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.39) by $0.10. The company had revenue of $2.20 million for the quarter, compared to the consensus estimate of $2.43 million. On average, analysts predict that Tetraphase Pharmaceuticals will post $-1.50 earnings per share for the current fiscal year.
Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.